Meeting
2022 ASCO Annual Meeting
Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
Authors
Alejandro Navarro
Vall d'Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain
Alejandro Navarro , Santiago Ponce Aix , Isidoro C. Barneto - Aranda , Egbert F. Smit , Jose Antonio Lopez-Vilariño , Antonio Nieto , Carmen Maria Kahatt , Ali Hassan Zeaiter , Sophie Cousin , Helge Bischoff , Jaromir Roubec , Konstantinos Syrigos , Luis Paz-Ares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02566993
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8524)
DOI
10.1200/JCO.2022.40.16_suppl.8524
Abstract #
8524
Poster Bd #
151
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
First Author: Luis G. Paz-Ares
Poster
2023 ASCO Annual Meeting
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
First Author: Sophie Cousin
Poster
2018 ASCO Annual Meeting
ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.
First Author: Anna F. Farago
Poster
2016 ASCO Annual Meeting
CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
First Author: Leora Horn